S. Jockusch

Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics

This study identifies HCV NS5A inhibitors as SARS-CoV-2 exonuclease inhibitors and shows synergy in combination with polymerase inhibitors to enhance antiviral efficacy.

Sofosbuvir Terminated RNA is More Resistant to SARS-CoV-2 Proofreader than RNA Terminated by Remdesivir

This study compares the resistance of SARS-CoV-2 RNA terminated by Sofosbuvir and Remdesivir to exonuclease proofreading, finding Sofosbuvir-terminated RNA more resistant.

A Library of Nucleotide Analogues Terminate RNA Synthesis Catalyzed by Polymerases of Coronaviruses Causing SARS and COVID-19

This paper evaluates nucleotide analogues as inhibitors of SARS-CoV and SARS-CoV-2 RdRp, identifying those that terminate RNA synthesis and resist viral exonuclease activity.

Triphosphates of the Two Components in DESCOVY and TRUVADA are Inhibitors of the SARS-CoV-2 Polymerase

The paper shows that the triphosphates of tenofovir and emtricitabine inhibit SARS-CoV-2 RNA-dependent RNA polymerase, suggesting potential use of DESCOVY and TRUVADA as PrEP for COVID-19.

Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase

This study shows that three nucleotide analogues inhibit SARS-CoV-2 polymerase by being incorporated and blocking further RNA synthesis.

Nucleotide Analogues as Inhibitors of Viral Polymerases

The paper investigates the potential of nucleotide analogues, specifically EPCLUSA, as inhibitors of viral polymerases in coronaviruses like 2019-nCoV, SARS, and MERS.